NOTTINGHAM, UK – In a monumental leap forward for oncology, scientists and clinicians in Nottingham have unveiled an ultra-rapid method for genetically diagnosing brain tumours, slashing the diagnostic waiting period from an agonizing six to eight weeks to an astonishing two hours. This groundbreaking innovation, developed by experts at the University of Nottingham and Nottingham University Hospitals (NUH) NHS Trust, promises to transform care for thousands of patients across the UK each year, offering not just speed, but also unprecedented accuracy and vital relief during an incredibly challenging time.
The revolutionary technique, detailed today in the prestigious journal Neuro-Oncology, has already demonstrated a 100% success rate in clinical application, delivering crucial diagnostic insights rapidly and cost-effectively. This advancement paves the way for immediate, informed treatment decisions, potentially altering the trajectory of care and improving outcomes for individuals battling aggressive brain cancers.
The Urgent Imperative for Speed: A Battle Against Time
Every day, 34 people in the UK receive the devastating news of a brain tumour diagnosis, contributing to more than 12,000 new cases annually. For those afflicted with the most aggressive forms of the disease, the average survival rate can tragically be less than a year. The current diagnostic pathway, while thorough, is fraught with delays that exact a heavy toll on patients and their families.
Traditional diagnosis relies on complex genetic tests to classify brain tumours accurately. Clinicians currently send tumour samples to centralised analysis facilities, a process that typically consumes six to eight weeks, and often longer, before full results are returned. This protracted wait is not merely an inconvenience; it is a period of immense psychological trauma, uncertainty, and anxiety for patients grappling with a life-threatening illness. Furthermore, these delays directly impede the commencement of critical treatments such as radiotherapy and chemotherapy, potentially diminishing their efficacy and compromising a patient’s chances of survival.
"The emotional burden of waiting weeks for a diagnosis is profound," explains Dr. Stuart Smith, a Neurosurgeon from the School of Medicine at the University of Nottingham and NUH. "Patients find this period incredibly difficult, adding significantly to the anxiety and worry at what is already a very challenging time in their lives."
The new method from Nottingham aims to eliminate this agonizing limbo, offering not just a diagnosis but also a pathway to quicker, more targeted intervention.
The Nottingham Breakthrough: Intraoperative Insight
The team of experts in Nottingham has engineered an ultra-rapid genetic diagnostic method that can provide comprehensive tumour classification within a mere couple of hours. Critically, this speed means that diagnostic information could potentially be made available to the surgeon during the operation itself, allowing for real-time, informed adjustments to surgical strategy. This capability represents a paradigm shift in neurosurgical practice, moving from post-operative analysis to intraoperative decision-making.
In the published study, the NUH team successfully deployed this novel approach during 50 brain tumour surgeries. Each instance saw diagnostic results delivered in under two hours from the start of the surgery, with detailed tumour classifications emerging within minutes of sequencing. Beyond this initial rapid assessment, the platform’s continuous sequencing capabilities facilitate a fully integrated diagnosis within 24 hours, providing a comprehensive genetic profile that guides subsequent treatment.
"Traditionally, the process of diagnosing brain tumours has been slow and expensive," Dr. Smith elaborates. "Now, with this new technology, we can do more for patients because we can get answers so much more quickly, which will have a much bigger influence on clinical decision making, in as little as two hours. This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy."
Unpacking the Science: How the Ultra-Rapid Method Works
The journey to a brain tumour diagnosis typically begins with an MRI scan to identify the presence of a mass. Following initial consultations, patients often undergo surgery to obtain a tumour sample. Historically, neuropathologists would visually inspect these specimens under a microscope to identify cell types. However, in recent years, the field has transitioned towards classifying tumours based on their underlying DNA and genetic abnormalities – a more precise, but until now, a more time-consuming process due to technological limitations.
Professor Matt Loose, a pioneering biologist from the School of Life Sciences at the University of Nottingham, is at the heart of this innovation. Professor Loose developed a method to sequence specific parts of human DNA at higher depth using portable sequencing devices from Oxford Nanopore Technologies. This ingenious approach allows relevant sections of the human genome to be examined much more rapidly, simultaneously sequencing multiple DNA regions and significantly accelerating the entire diagnostic process.
The new system leverages the power of Oxford Nanopore’s P2 PromethION sequencers and a bespoke software tool named ROBIN. These devices operate by detecting changes in electrical current as single molecules of DNA pass through a ‘nanopore’ – an incredibly tiny hole in a membrane. This real-time detection allows for incredibly fast and efficient sequencing.
"When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient," Professor Loose recounts. "This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how can it be treated. Combined with our later research where we were able to look at relevant parts of the human genome more quickly – then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly."
Once a sample is removed during surgery and sent to the pathology lab for DNA extraction, it is then transferred to Professor Loose’s team for sequencing. "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need," Professor Loose explains. "Methylation is the one we are most interested in early on in this instance because that defines the tumour type." Methylation patterns on DNA act like genetic fingerprints, providing crucial information about a tumour’s origin, aggression, and potential response to treatment.
Beyond Speed: Enhanced Accuracy and Cost-Effectiveness
The benefits of this new diagnostic method extend beyond mere speed. Dr. Simon Paine, a Consultant Neuropathologist at NUH, emphasizes the profound impact on diagnostic quality. "This new method of diagnosing brain tumours is going to be a game changer; it really is revolutionary. It not only increases the speed at which the results will be available, but the degree of accuracy of the diagnosis as well is incredible."
This enhanced accuracy is critical. A precise genetic classification allows clinicians to select the most effective, targeted treatments, moving away from a one-size-fits-all approach towards truly personalised medicine.
Furthermore, the Nottingham team has also highlighted the significant economic advantages of their innovation. "Not only is the test more accurate and quicker, but it is also cheaper than current methods," Professor Loose asserts. "Our calculations stand at around £450 per person, potentially less when scaled up. There are a few reasons for this. Our method can eliminate the need for four to five separate tests, reducing costs as a consequence as we are getting more information from the single test we do. Most importantly, it delivers results to the patients when they need them." This cost-effectiveness makes the widespread adoption of this technology a realistic and attractive prospect for the NHS.
Official Responses and Broader Implications
The announcement has been met with enthusiastic support from key figures in brain tumour research and patient advocacy.
Dr. Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, lauded the transformative potential of the breakthrough. "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients, ensuring rapid access to the optimal standard of care and – crucially – removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis."
Dr. Newman also underscored the wider healthcare implications: "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis. The BRAIN MATRIX Trial, funded by the Brain Tumour Charity, is now exploring how this technology can match patients to personalised clinical trials across the UK." This linkage to clinical trials is particularly exciting, as it means patients could be fast-tracked into innovative, experimental treatments tailored to their tumour’s specific genetic makeup.
A Future of Precision and Hope
The implications of this Nottingham-led innovation are far-reaching. For patients, it promises to alleviate immense psychological distress, replace agonizing uncertainty with timely answers, and accelerate access to life-saving treatments. For clinicians, it offers unprecedented insight, empowering them to make more informed surgical and therapeutic decisions, potentially even during the operation itself. For the healthcare system, it presents a more efficient, accurate, and cost-effective diagnostic pathway.
The Nottingham team is now actively working towards rolling out this revolutionary testing method across other NHS Trusts throughout the UK. This national implementation would ensure that all brain tumour patients, regardless of their location, can benefit from this cutting-edge diagnostic capability, ushering in an era of faster, more precise, and ultimately more hopeful care.
This breakthrough is not just a scientific achievement; it is a testament to the power of collaborative research between university scientists and frontline clinicians, united by a shared mission to improve patient lives. As the technology expands, it holds the potential to redefine the standard of care for brain tumour patients, offering a beacon of hope where once there was only a long, anxious wait.
About the Author
